Efoora Inc. develops rapid diagnostic tests and biosensors for testing and diagnosing diseases including HIV, Hepatitis B and C, malaria, pregnancy, bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD). The company is headquartered in Buffalo Grove, Illinois.
| Revenue (TTM) | $3.97B |
| Gross Profit (TTM) | $1.13B |
| EBITDA | $340.40M |
| Operating Margin | 5.06% |
| Return on Equity | 4.57% |
| Return on Assets | 3.79% |
| Revenue/Share (TTM) | $94.22 |
| Book Value | $44.03 |
| Price-to-Book | 0.72 |
| Price-to-Sales (TTM) | 0.32 |
| EV/Revenue | 0.651 |
| EV/EBITDA | 8.30 |
| Quarterly Earnings Growth (YoY) | -48.20% |
| Quarterly Revenue Growth (YoY) | -1.30% |
| Shares Outstanding | $41.00M |
| Float | $37.35M |
| % Insiders | 3.37% |
| % Institutions | 109.76% |
Volatility is currently contracting
Everforth (EFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
EFOR, MTCH and NTTYY made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 12, 2026.
SHG, EFOR and LTM made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 10, 2026.
VLO, EFOR and AMP made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 5th, 2026.
Discover why EFOR, KFRC and KFY stand out as top staffing stocks, driven by AI adoption, strong execution, resilient demand and growth.
EFOR, AER and SANM made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 31, 2026.
Everforth, Inc. (EFOR) Q2 2026 Earnings Call Transcript
RICHMOND, Va.--(BUSINESS WIRE)---- $EFOR #AI--Everforth, Inc. (NYSE: EFOR), a leading technology and digital engineering company, reported financial results for the quarter ended June 30, 2026. Highlights Second Quarter 2026 Revenues were $1,007.0 million Net income was $14.2 million Adjusted EBITDA (a non-GAAP measure) was $96.7 million (9.6 percent of revenues) Operating cash flows were $52.2 million and Free Cash Flow (a non-GAAP measure) was $46.3 million Repurchased 0.4 million shares of the Company's c.
Everforth, Inc. is rated Hold ahead of second-quarter earnings, with a central-case fair value of $20–$25 per share versus the July 22 closing price of $20.38. EFOR trades at roughly 6x EV/EBITDA, reflecting market skepticism that margins will recover toward late-2025 levels and continued concerns about AI-driven demand across the IT services sector, despite healthy free. Balance sheet leverage, rather than operating performance, remains the primary constraint on upside. Net debt is approximately 159% of market capitalization, amplifying equity sensitivity despite the company's July refinancing.
RICHMOND, Va.--(BUSINESS WIRE)---- $efor #AI--Everforth, Inc. (NYSE: EFOR), a leading technology and digital engineering firm, announced today that the Company has successfully completed the refinancing and upsizing of its $500 million Revolving Credit Facility (“Revolver”), with a new five-year $600 million facility, extending the maturity date from 2028 to 2031. “The successful refinancing and upsizing of our credit facility reflects the strength of our balance sheet, the durability of our free cash flow g.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EFOR and any ticker you trade — then tracks every position and per-strategy win rate.
